Conditions: Hepatitis C
Keywords: Chronic Hepatitis C Protease Inhibitor Telaprevir Peginterferon Alfa-2b Ribavirin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 189
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: MP-424 intervention 2: Ribavirin intervention 3: Peginterferon Alfa-2b intervention 4: Ribavirin intervention 5: Peginterferon Alfa-2b
Intervention descriptions: intervention 1: 750 mg every 8 hours for 12 weeks intervention 2: 600 - 1000 mg/day based on body weight for 24 weeks intervention 3: 1.5 mcg/kg/week for 24 weeks intervention 4: 600 - 1000 mg/day based on body weight for 48 weeks intervention 5: 1.5 mcg/kg/week for 48 weeks

Protocol document: